ABSTRACT
Objective: This prospective study aimed to investigate the effects of the selective angiotensin receptor antagonist, telmisartan, on microalbuminuria after coronary artery bypass surgery in patients with diabetes mellitus.Methods: Patients were divided into two groups with block randomisation, using the sealed envelope technique: group T (telmisartan group) consisted of patients who received the angiotensin receptor blocking agent telmisartan 80 mg daily for at least six months in the pre-operative period; group N-T (non-telmisartan group) consisted of patients who received no telmisartan treatment. Clinical and demographic characteristics, operative and postoperative features, microalbuminuria and high-sensitivity C-reactive protein levels were compared.Results: Forty patients met the eligibility criteria for the study. The groups did not differ with regard to clinical and demographic characteristics, and operative and postoperative features. Microalbuminuria levels between the groups differed significantly in the pre-operative period, first hour postoperatively and fifth day postoperatively. C-reactive protein levels between the groups differed significantly on the fifth day postoperatively.Conclusion: Telmisartan was useful for decreasing systemic inflammation and levels of urinary albumin excretion in patients who had type 2 diabetes mellitus and had undergone coronary artery bypass surgery
Subject(s)
Postoperative Period , South AfricaABSTRACT
Aims: The objective of our study is to compare the efficiency and safety of fentanyl citrate-midazolam-propofol combination with fentanyl citrate-ketamine-propofol combination used as sedative and analgesic medication in patients undergoing ERCP procedure. Study Design: Randomized and prospective. Place and Duration of Study: Department of Anaesthesiology and Reanimation (Gastroenterology Unit) between June 2009 and June 2010. Methodology: 103 patients undergoing ERCP aged between 20-80 years, ASA I-III, participated in our study. Cases were randomly divided into two groups as group M(n=51) and group K(n=52). Fentanyl citrate 1 μg/kg IV was infused to all patients 5 minutes before the process. Group M: In addition to fentanyl, midazolam 0.04 mg/kg IV and propofol loading dose of 1mg/kg IV and maintenance dose of 4mg/kg/h IV were also infused. Group K: In addition to fentanyl, ketamine 0.5mg/kg IV and propofol loading dose of 1mg/kg IV and maintenance dose of 4mg/kg/h IV were infused as well. At the end of ERCP procedure, propofol infusion was terminated. The time required for the Richmond Alertness-Sedation Scale (RASS) score to reach -1 (recovery period) and its change from -1 to 0 in recovery room (discharge period) and also the development of side effects during the practice were recorded. After recovery period the patients were questioned if they felt pain during the procedure or not. If they felt any, the pain was evaluated according to Visual Analog Scale (VAS) score. Results: Recovery period, discharge period and satisfaction of the endoscopist were similar between the two groups, however cardiovascular and respiratory system parameters were more stable in patients in Group K. Conclusion: Our study pointed that fentanyl citrate-ketamine-propofol combination is probably preferable over fentanyl citrate-midazolam-propofol combination in terms of cardiovascular and respiratory stability during sedation in ERCP procedures.
ABSTRACT
OBJECTIVE: This study aimed to determine a possible correlation between oral mucosal disease and salivary concentrations of the antimicrobial peptides human beta-defensin-1 (hβD-1) and human betadefensin- 2 (hβD-2). METHOD: The present work focussed on the establishment of a reversed phase-high performance liquid chromatography (RP-HPLC) procedure to quantify human beta-defensins (hβD-1 and hβD-2) in saliva samples of patients with oral diseases such as lichen planus (n = 10), Behçet (n = 10) and recurrent apthous stomatitis (n = 10). RESULTS: Linear calibration range for hβD-1 and hβD-2 defensins was 1.67−200 µg mL-1 and 3.13− 100 µg mL-1 with R2 values of 0.9998 and 0.996, correspondingly. The concentration of beta-defensins in saliva was determined by comparing the peak areas of eluted hβD-1 and hβD-2 with that of their standards. The variation of the amount of beta-defensins was evaluated by comparisons of the results obtained from the patients with oral mucosal diseases before and after treatments and the control subjects. The limit of detection (LOD) and limit of quantification (LOQ) were found to be 1.62 µg mL- 1 and 5.39 µg mL-1 for hβD-1 and 0.94 µg mL-1 and 3.13 µg mL-1 for hβD-2, respectively. CONCLUSION: The salivary beta-defensin concentration was significantly higher in patients with oral mucosal diseases than in healthy volunteers; furthermore, in patients with oral mucosal diseases, the concentration was significantly higher before treatment than after treatment.
OBJETIVO: Este estudio tuvo por objeto determinar una posible correlación entre la enfermedad de la mucosa oral y las concentraciones salivales de la beta-defensina humana 1 (hβD-1) y la beta-defensina humana 2 (hβD-2) de los péptidos antimicrobianos. MÉTODO: El presente trabajo estuvo encaminado al establecimiento de un procedimiento de cromatografía líquida de alta eficacia de fase reversa (RP-HPLC) para cuantificar las beta-defensinas humanas (hβD-1 y hβD-2) en muestras de saliva de pacientes con enfermedades orales como el liquen plano (n = 10), Behçet (n = 10), y la estomatitis aftosa recurrente (n = 10). RESULTADOS: El rango de calibración lineal de las defensinas hβD-1 y hβD-2 fue 1.67-200 µg mL-1 y 3.13-100 µg mL-1 con valores R2 de 0.9998 y 996, respectivamente. La concentración de beta-defensinas en la saliva se determinó utilizando el área de sus estándares. La variación de la cantidad de beta defensinas fue evaluada por comparaciones de los resultados obtenidos de los pacientes con enfermedades de la mucosa oral, antes y después de los tratamientos y los sujetos de control. Se halló que el límite de detección (LDD) y el límite de cuantificación (LDC) fueron 1.62 µg mL-1 y 5.39 µg mL- 1 para hβD-1 y 0.94 µg mL-1 y 3.13 µg mL-1 hβD-2, respectivamente. CONCLUSIÓN: La concentración de beta-defensina salival fue significativamente mayor en los pacientes con enfermedades de la mucosa oral que en los voluntarios sanos. Además, en pacientes con enfermedades de la mucosa oral, la concentración fue significativamente mayor antes del tratamiento que después del tratamiento.
Subject(s)
Humans , Male , Female , Adolescent , Adult , Middle Aged , Aged , Young Adult , Saliva/chemistry , Stomatitis, Aphthous/metabolism , Behcet Syndrome/metabolism , beta-Defensins/metabolism , Lichen Planus/metabolism , Stomatitis, Aphthous/therapy , Biomarkers/metabolism , Case-Control Studies , Behcet Syndrome/therapy , Chromatography, High Pressure Liquid , Lichen Planus/therapy , Mouth MucosaABSTRACT
Intraosseous ganglion cysts of the carpal bones located in the lunate are one of the rarely seen pathologic conditions. Here we present a case of the penetrating type of intraosseous ganglion cyst located in the lunate as an uncommon cause of wrist pain. The patient was successfully treated by surgical intervention. Intraosseous ganglion cyst should be considered in the differential diagnosis of chronic dull wrist pain.
Los gangliones intraóseos de los huesos carpianos localizados en el semilunar, constituyen una de las condiciones patológicas más raras que puedan verse. Aquí presentamos un caso del tipo penetrante de ganglión intraóseo, localizado en el semilunar como causa poco común del dolor de muñeca. El paciente fue tratado exitosamente mediante una intervención quirúrgica. El quiste ganglionar intraóseo debe ser considerado en el diagnóstico diferencial de dolores de muñeca sordos que se han hecho sentir por mucho tiempo, y se han vuelto crónicos.